Why Novo Nordisk should buy Uniqure
Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.
Novo goes early to leapfrog haemophilia gene therapies
Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.
Pricing questions remain as Novo gets the nod for oral sema
Novo Nordisk says that oral semaglutide’s list price will be “similar” to Ozempic’s, but it will be a while before its true cost becomes apparent.
Should the diabetes development road end for Sanofi?
Sanofi has said goodbye to Lexicon, but after years of failing to keep up with rivals, there is scope for the French drug maker to make more drastic cuts to its diabetes…
Go or no go? Novo awaits call on oral sema
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
Boehringer splashes the cash in Nash
Paying $40m up front for a preclinical asset is a bold move, even for the red-hot Nash space, though Boehringer has shelled out here before.
ADA 2019 – another gut punch for Lilly
Lilly is still trying to find a therapeutic window following gastrointestinal issues with its brightest pipeline hope, the GIP/GLP1 agonist tirzepatide.
ADA 2019 – Rewind makes Lilly’s Trulicity look average
Less than emphatic cardiovascular outcomes data leave Lilly looking vulnerable to Novo Nordisk’s competing drugs.
VTV’s diabetes reinvention gains some ground
After crashing on a late-stage Alzheimer’s failure last year VTV Therapeutics has taken a small step forward in type 1 diabetes.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.